MX2019010717A - Derivados de indol como inhibidores de bomba de eflujo. - Google Patents

Derivados de indol como inhibidores de bomba de eflujo.

Info

Publication number
MX2019010717A
MX2019010717A MX2019010717A MX2019010717A MX2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A MX 2019010717 A MX2019010717 A MX 2019010717A
Authority
MX
Mexico
Prior art keywords
inhibitors
indole
pump
formula
compounds
Prior art date
Application number
MX2019010717A
Other languages
English (en)
Spanish (es)
Inventor
J Lavoie Edmond
K Parhi Ajit
Yuan Yi
Zhang Yongzheng
Sun Yangsheng
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of MX2019010717A publication Critical patent/MX2019010717A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
MX2019010717A 2017-03-10 2018-03-09 Derivados de indol como inhibidores de bomba de eflujo. MX2019010717A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469987P 2017-03-10 2017-03-10
US201762523154P 2017-06-21 2017-06-21
PCT/US2018/021848 WO2018165611A1 (en) 2017-03-10 2018-03-09 Indole derivatives as efflux pump inhibitors

Publications (1)

Publication Number Publication Date
MX2019010717A true MX2019010717A (es) 2019-12-05

Family

ID=62044950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010717A MX2019010717A (es) 2017-03-10 2018-03-09 Derivados de indol como inhibidores de bomba de eflujo.

Country Status (12)

Country Link
US (1) US11993571B2 (cg-RX-API-DMAC7.html)
EP (1) EP3592736A1 (cg-RX-API-DMAC7.html)
JP (1) JP7323179B2 (cg-RX-API-DMAC7.html)
KR (1) KR102697360B1 (cg-RX-API-DMAC7.html)
CN (1) CN110770224B (cg-RX-API-DMAC7.html)
AU (1) AU2018231120B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018691A2 (cg-RX-API-DMAC7.html)
CA (1) CA3061238A1 (cg-RX-API-DMAC7.html)
IL (1) IL269210B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019010717A (cg-RX-API-DMAC7.html)
SG (1) SG11201908351TA (cg-RX-API-DMAC7.html)
WO (1) WO2018165611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147335A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2017147333A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
AU2018231120B2 (en) 2017-03-10 2022-06-23 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
WO2018165614A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3630109A4 (en) 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey BACTERIAL EFFLUX PUMP INHIBITORS
US11458121B2 (en) 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
WO2019099402A1 (en) * 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
KR102704123B1 (ko) 2019-11-01 2024-09-06 에스엘 주식회사 차량용 램프
WO2025043115A1 (en) 2023-08-23 2025-02-27 Taxis Pharmaceuticals, Inc. Bacterial efflux pump inhibitors
WO2025049604A1 (en) * 2023-08-29 2025-03-06 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
US3465080A (en) * 1968-10-07 1969-09-02 American Cyanamid Co Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression
US3978224A (en) 1975-07-01 1976-08-31 Schering Corporation Antimicrobial halo-substituted-2-cyanoethylaminoalkyl-3-phenyl-indoles
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1992004017A1 (en) 1990-09-10 1992-03-19 The Upjohn Company Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
US5663152A (en) 1995-01-19 1997-09-02 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators for aminoglycosides
US6506339B1 (en) * 1997-02-10 2003-01-14 Biomedical Design, Inc. Method of sterilization
WO1999037667A1 (en) * 1998-01-23 1999-07-29 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6204279B1 (en) 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
US6326391B1 (en) 1998-12-04 2001-12-04 Influx, Inc. Inhibitors of multidrug transporters
AU7866300A (en) 1999-10-08 2001-04-23 Smithkline Beecham Corporation Fab i inhibitors
US6730684B1 (en) * 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
WO2011101710A1 (en) 2010-02-16 2011-08-25 Wockhardt Research Centre Efflux pump inhibitors
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
HUP0103986A2 (hu) * 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2004062674A2 (en) 2003-01-07 2004-07-29 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
AU2005245962A1 (en) 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
US7855228B2 (en) 2005-02-10 2010-12-21 The Board Of Trustees Of The Leland Stamford Junior University Antibiotics targeting MreB
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
FR2904317A1 (fr) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
WO2009110002A1 (en) 2008-03-05 2009-09-11 Council Of Scientific & Industrial Research Novel efflux pump inhibitors
WO2010033168A2 (en) 2008-09-18 2010-03-25 Renovis, Inc. Amide compounds, compositions and uses thereof
EP2414368B1 (en) 2009-04-03 2013-11-27 Achillion Pharmaceuticals, Inc. Hydroxythienoquinolones and related compounds as anti-infective agents
EP2394653A1 (en) * 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
FR2969150B1 (fr) * 2010-12-20 2013-07-26 Centre Nat Rech Scient Nouvelles molecules indoliques demontrant des activites antibacteriennes dans une variete de bacteries a gram-negatif et positif dont des bacteries multidrogues-resistantes
JP6223452B2 (ja) 2012-09-07 2017-11-01 ノバルティス アーゲー インドールカルボキサミド誘導体およびその使用
WO2014078294A1 (en) * 2012-11-13 2014-05-22 Memorial Sloan-Kettering Cancer Center Indole compounds and their use as antimicrobials
WO2015164482A1 (en) 2014-04-22 2015-10-29 The Johns Hopkins University Inhibitors of drug-resistant mycobacterium tuberculosis
CA2960275A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
US9926261B2 (en) 2015-03-10 2018-03-27 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US9950993B2 (en) 2015-03-13 2018-04-24 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3307725A1 (en) 2015-06-11 2018-04-18 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
EP3331530A4 (en) * 2015-08-03 2018-12-19 Raze Therapeutics Inc. Mthfd2 inhibitors and uses thereof
WO2017147335A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2017147333A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
ES2968227T3 (es) * 2016-12-23 2024-05-08 Aquinnah Pharmaceuticals Inc Compuestos, composiciones y procedimientos de uso
AU2018231120B2 (en) 2017-03-10 2022-06-23 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
WO2018165614A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3630109A4 (en) 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey BACTERIAL EFFLUX PUMP INHIBITORS
US11458121B2 (en) * 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
US20190031624A1 (en) 2017-07-28 2019-01-31 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
WO2019099402A1 (en) * 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection

Also Published As

Publication number Publication date
US11993571B2 (en) 2024-05-28
IL269210A (en) 2019-11-28
EP3592736A1 (en) 2020-01-15
WO2018165611A1 (en) 2018-09-13
AU2018231120B2 (en) 2022-06-23
CA3061238A1 (en) 2018-09-13
SG11201908351TA (en) 2019-10-30
KR20190138790A (ko) 2019-12-16
IL269210B1 (en) 2025-01-01
KR102697360B1 (ko) 2024-08-20
US20210094912A1 (en) 2021-04-01
IL269210B2 (en) 2025-05-01
BR112019018691A2 (pt) 2020-04-07
JP2020510044A (ja) 2020-04-02
JP7323179B2 (ja) 2023-08-08
CN110770224A (zh) 2020-02-07
CN110770224B (zh) 2022-11-18
AU2018231120A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2019010717A (es) Derivados de indol como inhibidores de bomba de eflujo.
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
CL2020002082A1 (es) Inhibidores pd-1/pd-l1.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CO2018009068A2 (es) Derivados de indol y azaindol haloalilamina como inhibidores de lisil oxidasas y usos de los mismos
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
ECSP17039611A (es) Derivados de quinazolina utilizados para tratar el vih
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
MX2017012558A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
UY36748A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
MX2018003301A (es) Inhibidores de pcna.
MX2018012541A (es) Inhibidores de bromodominios.
CR20150571A (es) Compuestos y composiciones terapéuticos
BR112015032595A8 (pt) inibidores de ido
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
UY36749A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CO2020005420A2 (es) Compuestos antibacterianos